Amol Akhade/LinkedIn
Apr 21, 2025, 16:59
Amol Akhade: Antibody-Drug Conjugates in SCLC
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on X:
“Antibody-Drug Conjugates (ADCs) in SCLC.
All active agents in 2L/3L+ setting – DLL3, B7-H3, SEZ6, TROP2 – summarized in one slide.
Includes payloads, companies, trials, ORR/PFS/OS, and toxicity profile
Which one do you think is the most promising one?
Don’t confuse this with Tarlatamab. That’s BiTE and Not ADC.”
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared his post on X, adding:
“Now just to compare BiTE Tarlatamab vs ADCs in SCLC.”
More posts featuring Amol Akhade.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 11, 2025, 18:14
May 11, 2025, 18:05
May 11, 2025, 17:07
May 11, 2025, 16:57
May 11, 2025, 16:49